NS Healthcare is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
SECTOR: Patient Care
Copan WASP
URL: https://www.copangroup.com/
Microbiology and virology research have been boosted by Covid-19, as laboratories worldwide work tirelessly to develop diagnostic assays and therapies at an unprecedented pace. Preanalytics – the first step of the diagnostic path – obtained the same attention, as contact tracing and diagnosis rely on fast and accurate sample collection and handling. Mario Savarese, CEO of Copan WASP, explains how the company took advantage of its innovative thinking to support laboratories under pressure in the pandemic.
Download White PaperDespite the unpredictable scenario caused by the pandemic, 2021 was another positive year for Copan. Behind a turnover of 395 million euros, the company has adopted a global industrial strategy and investments aimed at sustainable development. Following these principles, the Group is preparing to face the challenges of the post-pandemic market.
Copan took the chance of the first in-person ECCMID of the last two years to give a name to its holistic approach to preanalytics. From sample collection to image analysis and data interpretation, meet Copan's WISE approach, which brings any sample to improved diagnostics.
